# To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

> **NCT06038916** · PHASE1,PHASE2 · COMPLETED · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 47 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** STSA-1002 Injection Placebo
- **DRUG:** STSA-1002 Injection

## Key facts

- **NCT ID:** NCT06038916
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-09
- **Primary completion:** 2025-03-20
- **Final completion:** 2025-04-27
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06038916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06038916, "To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06038916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*